精选85CNBC 财经（RSS）股市多源精选 ×3
诺和诺德心脏病药物试验失败，股价大跌
Novo Nordisk shares dive after heart medicine fails trial, dealing another blow toits pipeline
推荐理由
重磅药企临床试验失败，直接影响股价和管线预期，值得投资者关注。
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
更进一步：量化金融体系
看懂新闻只是起点——沿量化金融路径，把它变成能交付的工程能力